How is the eurocrisis hitting pharma and what are the risks?
This article was originally published in Scrip
Executive Summary
This time last year, the idea that a eurozone country might have to abandon the currency was a fairly outlandish one. But the tumult of the past 12 months has seen old certainties dissolve, and even if it is still generally thought that such an eventuality is unlikely, the means of avoiding it are far from decided and the risk is real. So real, in fact, that in Deloitte's most recent survey of UK CFOs, the risk of a break-up of the euro was their biggest single worry.